Vectorite Biomedical (ROCO:4170) Net Margin %: 333.68% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4170 Vectorite Biomedical Inc ROCO:4170
65 GF Score
Price NT$12.50
GF Value NT$17.56
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Vectorite Biomedical Net Margin %?

Vectorite Biomedical ROCO:4170 +0.81% 65 Net Margin % is 333.68% as of Dec. 2025. GuruFocus rates ROCO:4170 with a GF Score™ of 65/100 and a GF Value™ of NT$17.56 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 941 Biotechnology companies, Vectorite Biomedical ranks better than 98.3% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Vectorite Biomedical's Net Income for the six months ended in Dec. 2025 was NT$92.35 Mil. Vectorite Biomedical's Revenue for the six months ended in Dec. 2025 was NT$27.68 Mil. Therefore, Vectorite Biomedical's net margin for the quarter that ended in Dec. 2025 was 333.68%.

The historical rank and industry rank for Vectorite Biomedical's Net Margin % or its related term are showing as below:

ROCO:4170' s Net Margin % Range Over the Past 10 Years
Min: -340.11   Med: -52.48   Max: 156.62
Current: 156.62

ROCO:4170's Net Margin % is ranked better than
98.3% of 941 companies
in the Biotechnology industry
Industry Median: -88.29 vs ROCO:4170: 156.62

Vectorite Biomedical  (ROCO:4170) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Vectorite Biomedical Net Margin % Related Terms

Vectorite Biomedical Net Margin % Historical Data

* Premium members only.

The historical data trend for Vectorite Biomedical's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vectorite Biomedical Net Margin % Chart

Vectorite Biomedical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.05 -61.55 -11.82 -69.33 156.62

Vectorite Biomedical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.93 -55.22 -79.08 11.34 333.68

ROCO:4170 vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Vectorite Biomedical's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vectorite Biomedical Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vectorite Biomedical's Net Margin % distribution charts can be found below:

* The bar in red indicates where Vectorite Biomedical's Net Margin % falls into.


ROCO:4170
65GF Score
Vectorite Biomedical Inc ROCO:4170
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vectorite Biomedical Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Vectorite Biomedical's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=96.174/61.406
=156.62 %

Vectorite Biomedical's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=92.349/27.676
=333.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 333.68% mean?
Vectorite Biomedical (ROCO:4170) has a Net Margin % of 333.68% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Vectorite Biomedical and its competitors. According to the industry distribution chart, Vectorite Biomedical ranks #16 out of 941 companies in the Biotechnology industry, placing it in the top 1.7%.
Is Vectorite Biomedical's Net Margin % too high?
Vectorite Biomedical's current Net Margin % is 333.68%. Based on the distribution chart, Vectorite Biomedical ranks #16 out of 941 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vectorite Biomedical has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vectorite Biomedical's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vectorite Biomedical ranks #16 out of 941 companies for Net Margin %. This places Vectorite Biomedical in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Vectorite Biomedical and its competitors. Vectorite Biomedical's current Net Margin % is 333.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectorite Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Vectorite Biomedical (ROCO:4170) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$17.56, compared to a current price of NT$12.50 — trading 28.8% below its estimated fair value. The current Net Margin % is 333.68%. Vectorite Biomedical's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Vectorite Biomedical (ROCO:4170), the current Net Margin % is 333.68% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vectorite Biomedical (ROCO:4170) Overvalued in 2026?

Based on GuruFocus' analysis, Vectorite Biomedical stock appears to be undervalued. The current stock price of NT$12.50 is trading 28.8% below its estimated GF Value™ of NT$17.56. GuruFocus considers Vectorite Biomedical to be Modestly Undervalued.

Key valuation signals for ROCO:4170:

  • Net Margin %: 333.68%
  • GF Value™: NT$17.56 vs. price of NT$12.50 (28.8% below fair value)
  • GF Score™: 65/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vectorite Biomedical Business Description

Address Number 97, Section 1, Xintai 5th Road, 6th Floor, Floor-11, Yuzhi District, New Taipei City, Taipei, TWN, 22175
Vectorite Biomedical Inc is a Taiwan-based biotechnology research and development, cell product (preparation) manufacturing and immune cell collection and storage business.
65GF Score

Get the complete analysis for ROCO:4170

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$12.50
Price
NT$17.56
GF Value